Skip to main content
. 2019 Aug 12;10:144. doi: 10.4103/ijpvm.IJPVM_111_18

Table 1.

The description of studies in EMRO and Middle East countries that met our eligibility criteria

Countries Authors’ names Pub. year Samples size HBsAg Positive (No) HBsAg Prevalence (%)
Iran (E & M) Asefzade, M 2004 270 3 1.1
Azarhoosh, R 2006 300 3 1
Bayani, M 2014 527 4 0.75
Binesh, F 2015 431 1 0.23
Salmanzadeh, SH 2016 188 4 2.1
Kamangar, E 2003 285 3 1.05
Salari, M 2006 406 5 1.23
Amini-Ranjbar, S 2008 83 8 9.6
Ghorbani, Gh 2010 112 3 2.6
Alavian, S.M 2008 83 0 0
Sharifi, M 2008 77 0 0
Baba Mahmoodi, F 2000 183 3 1.6
Khosravani, A 2012 222 0 0
Mokhayeri, H 2016 462 7 1.52
Torkzaban, P 2009 123 4 3.5
Yarmohammadi, M 2010 191 0 0
Ranjbar, M 2001 130 1 0.77
Iraq (E & M) Al-Mashhadani, J. I 2009 1656 89 5.37
Hussein, N. R 2015 192 1 0.52
Hamied, L 2010 375 25 6.66
Libya (E & M) Elzouki, A. N 2014 601 11 1.83
Ziglam, H 2013 2705 31 1.1
Morocco (E) Djeriri, K 2008 276 3 1
Souly, K 2016 601 19 3.16
Pakistan (E) Abdul Qayyum, F 2012 1891 27 1.4
Aziz, S 2002 250 6 2.4
Memon, M. S 2007 380 18 4.7
Saqib, Sh 2016 500 3 0.6
Palestine (E & M) Astal, Z 2004 399 11 2.75
Sudan (E) Elduma, A. H 2011 245 12 4.9
Elmukashfi, T. A 2012 843 51 6.04
Elmukashfi, T. A 2016 385 62 16.1
Nail, A 2008 211 5 2.4
Saudi Arabia (E & M) Alqahtani, J. M 2014 300 1 0.33
Turkey (M) Fatma, E. T 2015 91185 2462 2.7
Ozsoy, M. F 2003 702 21 3
Bosnak, V. K 2013 199 1 0.5
Guven, R 2006 571 2 0.35
Erden, S 2003 109 7 6.4
Irmak, Z 2010 147 1 0.68
Kosgeroglu, N 2004 595 16 2.68
Tozun, N 2015 245 3 1.23
Yemen (E & M) Shidrawi, R 2004 543 54 9.9
Pooled Estimate* - - 110179 2991 2.77 (2.64-2.83)≤

*Pooled estimate by random-effects Meta analyses≤95% confidence interval (in brackets); (E: EMRO countries; M: Middle East countries; E & M: All countries from two regions)